Product nameAnti-Ryanodine Receptor antibody
See all Ryanodine Receptor primary antibodies
DescriptionRabbit polyclonal to Ryanodine Receptor
Tested applicationsSuitable for: WB, IHC-P, IHC-Frmore details
Species reactivityReacts with: Horse, Human
Predicted to work with: Mouse, Rat
Synthetic peptide derived from C terminal domain of Human Ryanodine Receptor protein
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferConstituent: Whole serum
Our Abpromise guarantee covers the use of ab90629 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2000. Predicted molecular weight: 565 kDa.|
|IHC-P||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
FunctionCalcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis.
Tissue specificitySkeletal muscle and brain (cerebellum and hippocampus).
Involvement in diseaseMalignant hyperthermia 1
Central core disease of muscle
Multiminicore disease with external ophthalmoplegia
Myopathy, congenital, with fiber-type disproportion
Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.
Sequence similaritiesBelongs to the ryanodine receptor (TC 1.A.3.1) family. RYR1 subfamily.
Contains 3 B30.2/SPRY domains.
Contains 5 MIR domains.
DomainThe calcium release channel activity resides in the C-terminal region while the remaining part of the protein constitutes the 'foot' structure spanning the junctional gap between the sarcoplasmic reticulum (SR) and the T-tubule.
modificationsChannel activity is modulated by phosphorylation. Phosphorylation at Ser-2843 may increase channel activity. Repeated very high-level exercise increases phosphorylation at Ser-2843.
Activated by reversible S-nitrosylation. Repeated very high-level exercise increases S-nitrosylation.
Cellular localizationSarcoplasmic reticulum membrane. Membrane. The number of predicted transmembrane domains varies between orthologs, but both N-terminus and C-terminus seem to be cytoplasmic.
- Information by UniProt
- Arrhythmogenic right ventricular dysplasia 2 antibody
- ARVC2 antibody
- ARVD2 antibody
ab90629 staining Ryanodine Receptor in frozen horse skeletal muscle tissue sections by Immunohistochemistry (Frozen sections).
Tissue was fixed with acetone and blocked with 10% serum for 1 hour. Samples were incubated with primary antibody (1/100 in diluent) for 12 hours at 4°C. An FITC-conjugated goat anti-rabbit polyclonal IgG (1/200) was used as the secondary antibody.
ab90629 has not yet been referenced specifically in any publications.